Clinical trials: Breast Cancer, Metastatic
Breast Cancer
Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer
This is a Phase III, randomized, multicenter, two-arm, open-label study designed to evaluate the safety and efficacy of trastuzumab emtansine compared with that of lapatinib + capecitabine in Chinese participants with…
- Trial name
- NCT03084939
- Testing
- Trastuzumab Emtansine, Lapatinib, Capecitabine
- Where
- 18 sites in China
- Volunteers
- 351 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
The purpose of this study is to determine the recommended phase 2 dose and overall safety and tolerability of TRC105 when given in combination with capecitabine for the treatment of patients with progressive or recurrent…
- Trial name
- TRC105 (NCT01326481)
- Testing
- TRC105, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Breast Cancer, Advanced Breast Cancer
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the use of lovastatin, a cholesterol-depleting pro-drug that may lower CAV-1 levels, in order to increase HER2 expression on the cell surface of cancer cells and enhance the uptake and…
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT07619365
- Testing
- Trastuzumab deruxtecan, Lovastatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Washington University School of Medicine
Metastatic Breast Cancer
Nurse AMIE: Addressing Metastatic Individuals Everyday
Determine the acceptability and feasibility of a supportive care software platform to improve quality of life and function in metastatic breast cancer patients.
- Trial name
- NurseAMIE (NCT03975621)
- Testing
- Supportive Care
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Milton S. Hershey Medical Center
Breast Reconstruction
Secondary Breast Reconstruction With a Flap of Skin From the Back
The purpose of this study is to examine the different outcomes of breast reconstruction in women who are treated for breast cancer with mastectomy and subsequently have delayed breast reconstruction by one of two different…
- Trial name
- NCT02169011
- Testing
- Latissimus Dorsi Flap Reconstruction, TAP Flap Reconstruction
- Where
- 4 sites in Denmark, Norway
- Volunteers
- 50 people
- Sponsor
- Vejle Hospital
Breast Cancer
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
Due to its remarkable activity as salvage treatment in women with metastatic breast cancer as well as the additive activity observed for gemcitabine administered in combination with trastuzumab, the clinical activity of the…
- Trial name
- NCT00193063
- Testing
- Trastuzumab, Gemcitabine
- Volunteers
- 41 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years
This open-label, randomized, multicenter study will evaluate participant preference for subcutaneous (SC) versus intravenous (IV) trastuzumab (Herceptin) in participants with HER2-positive metastatic breast cancer responding to…
- Trial name
- NCT01810393
- Testing
- Trastuzumab
- Where
- 61 sites in France
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Her2 Positive Metastatic Breast Cancer
The Myocet/Lapatinib Study. ICORG 10-03, V5
This study is a Phase I/II open label, multi-centre trial. Patients with HER2+ve metastatic breast cancer, following disease progression during, or after, treatment with trastuzumab and taxanes, will be treated with Lapatinib…
- Trial name
- NCT01495884
- Testing
- non-pegylated liposomal doxorubicon (Myocet™), Lapatinib (Tyverb™)
- Where
- 10 sites in Ireland
- Volunteers
- 11 people
- Sponsor
- Cancer Trials Ireland
Breast Cancer
An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)
This single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously…
- Trial name
- NCT01277133
- Where
- Romania
- Volunteers
- 83 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Leptomeningeal Metastasis
Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.
This is a multicenter, interventional, prospective study among breast cancer patients with a suspicion of metastatic meningitis.
- Trial name
- NCT03974204
- Testing
- Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment, Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are "Lack of evidence" according to EANO-ESMO classification, Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are "confirmed", "probable" or "possible", leading to leptomeningeal metastase specific treatment
- Where
- 2 sites in France
- Sponsor
- Centre Oscar Lambret
Breast Cancer, Cardiovascular Diseases
Cardiac Rehabilitation for Breast Cancer Survivors
Women with breast cancer treated using anthracyclines and/or trastuzumab are at an increased risk of cardiovascular disease (CVD) following treatment completion.
- Trial name
- NCT06251401
- Testing
- In-person supervised cardiac rehabilitation, Virtual cardiac rehabilitation
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Women's College Hospital
Breast Cancer
Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
RATIONALE: The monoclonal antibody trastuzumab can locate breast cancer cells that have HER2 on their surface and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00057993
- Testing
- trastuzumab, exemestane
- Sponsor
- Northwestern University
Breast Cancer
C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
The purpose of this research project is to create images of where and how the amino acid (the building blocks of proteins)Tryptophan is processed in normal and abnormal tissue in the patient's body.
- Trial name
- NCT01302821
- Testing
- Adenovirus-p53 transduced dendritic cell vaccine, 1-methyl-D-tryptophan, Carbon C 11 alpha-methyltryptophan
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Breast Cancer
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
This open-label, single-center Phase Ib study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) with Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer.
- Trial name
- STELA (NCT02073916)
- Testing
- T-DM1, Lapatinib, Abraxane
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jenny C. Chang, MD
Ovarian Neoplasms, Colorectal Neoplasms
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Doctors will take some tissue from the tissue removed during surgery in order to study how the blood vessels of the tumor respond to radiation therapy.
- Conditions
- Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer
- Trial name
- NCT00132704
- Testing
- Ionizing radiation (IR) therapy, Ionizing radiation (IR)
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy.
- Trial name
- RAGE (NCT05256745)
- Testing
- TTP488, ddAC/ddT, TC
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Georgetown University
HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
This study aims to evaluate the efficacy and safety of adding the anti-angiogenic agent anlotinib to the combination of the CDK2/4/6 inhibitor Culmerciclib and endocrine therapy in patients with HR+/HER2- breast cancer and brain…
- Trial name
- NCT07745257
- Testing
- Culmerciclib, Anlotinib, Endocrine Therapy
- Where
- 9 sites in China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Breast Neoplasms, HER-2 Gene Amplification
Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer
This retrospective study evaluated the efficacy and the safety of use of this treatment combined with a taxane for the treatment of HER2-positive metastatic breast cancer and compared the clinical and demographic characteristics…
- Trial name
- EPTTCSM (NCT03979911)
- Where
- France
- Volunteers
- 63 people
- Sponsor
- University Hospital, Brest
Fatigue, Breast Cancer
Eurythmy Therapy (ERYT) as a Treatment Option for Fatigue in Metastatic Breast Cancer Patients
Cancer related fatigue (CRF) is the most burdening symptom in breast cancer patients, and prevalence exceeds 75% in patients with metastatic disease.
- Trial name
- ERYT (NCT04024267)
- Testing
- Eurythmy therapy, CoordiFit
- Where
- 11 sites in Switzerland
- Volunteers
- 19 people
- Sponsor
- University of Bern
Breast Neoplasms
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants…
- Trial name
- NCT02756364
- Testing
- Fulvestrant, Sapanisertib
- Where
- 53 sites in United States, Spain
- Volunteers
- 141 people
- Sponsor
- Calithera Biosciences, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.